Abstract
Melanoma is the most lethal cutaneous malignancy that threatens human lives. Poor sensitivity to chemotherapy drugs and the high rate of resistance are the bottlenecks of melanoma treatment. Thus, new chemotherapy drugs are needed. Drug repurposing is a safe, economical and timesaving way to explore new chemotherapy for diseases. Here, we investigated the possibility of repurposing the antibiotic monensin as an anti-melanoma agent. Using three human melanoma cells and two nomal human cell lines as cell models, we found that monensin is obviously toxic to human melanoma cells while safe to nomal human cells. It effectively inhibited cell proliferation and viability, while promoted apoptosis and differentiation of human melanoma cells in vitro. By establishment of an animal model of transplanted human melanoma in nude mice, we demonstrated that monensin suppressed the growth of xenografts in vivo. At the same time, we found that melanogenesis increased and the ability of sphere and cloning forming of melanoma decreased under the treatment of monensin. Further detection about differentiation and pluripotent regulations were executed. Our results suggest that monensin is a potent inhibitor of melanoma, and its anti-tumor mechanism ...Continue Reading
References
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Woo H ParkYoung Y Lee
Apr 14, 2006·Mayo Clinic Proceedings·Deborah L CumminsArjun Chanmugam
Feb 27, 2008·Blood·Zhen-Yi Wang, Zhu Chen
Dec 17, 2010·Molecular Cancer Therapeutics·Kirsi KetolaKristiina Iljin
Jun 20, 2012·International Journal of Molecular Medicine·Haiying GuoTian Yang
Feb 26, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GuptaM R Middleton
Apr 10, 2014·PloS One·Sheng WenGuanghui Wei
May 3, 2014·Gene Therapy·N WuT-C He
May 23, 2014·PloS One·Ning WangTong-Chuan He
Feb 6, 2015·International Journal of Oncology·Yukio NishimuraKazuyuki Itoh
Mar 31, 2015·Genes & Diseases·Xiang ChenTong-Chuan He
Dec 8, 2015·Scientific Reports·Youlin DengLiangdan Tang
Dec 8, 2016·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·V C AmannJ Mangana
Nov 5, 2017·Oncotarget·Merope GriffinSophia N Karagiannis